跳转至内容
Merck
CN

N0290

Sigma-Aldrich

硝唑尼特

≥98% (HPLC)

别名:

NTZ; 2-乙酸基-N-(5-硝基-2-噻唑基)苯甲酰胺

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C12H9N3O5S
CAS号:
分子量:
307.28
EC 号:
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77

质量水平

检测方案

≥98% (HPLC)

形式

powder

创始人

Romark

储存温度

2-8°C

SMILES字符串

CC(=O)Oc1ccccc1C(=O)Nc2ncc(s2)[N+]([O-])=O

InChI

1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)

InChI key

YQNQNVDNTFHQSW-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

硝唑尼特(NTZ)是一种噻唑化物类(thiazolide)化合物,它是一种结构与氯硝柳胺相似的抗寄生虫药。

应用

硝唑尼特已被用于:
  • 测试其对基孔肯雅病毒的抗病毒活性
  • 作为抗原生动物剂用于测试其对多种癌细胞系细胞活力的影响
  • 测试其对感染人巨细胞病毒(HCMV)的人成纤维细胞HFF细胞的影响

生化/生理作用

硝唑尼特是丙酮酸-铁氧还蛋白氧化还原酶(PFOR)抑制剂,FDA批准的抗寄生虫药(2002)。近期研究(C & EN Sept. 14, 2009, p. 28)表明,硝唑尼特可杀死非复制和复制的结核菌,未检测到明显的耐药性。
硝唑尼特(NTZ)通过作用于激酶信号传导通路来促进自噬,并作用于分枝杆菌中雷帕霉素复合物1(mTORC1)的哺乳动物靶点。体外研究中,它具有抗病毒特性,并有效地阻止了基孔肯雅病毒的进入和释放。NTZ还可以抑制早期阶段的日本脑炎病毒(JEV)感染,并具有治疗其他病毒感染的潜力,包括登革热、乙型肝炎(HBV)、冠状病毒和人类免疫缺陷病毒(HIV)。它具有抗恶性肿瘤功能,并可通过促进原癌基因c-Myc抑制来诱导细胞凋亡,从而导致肿瘤抑制。

特点和优势

该化合物由 Romark 开发。要浏览其他制药公司开发的化合物列表批准的药物/候选药物的列表, 点击这里

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Andrew Hemphill et al.
Expert opinion on pharmacotherapy, 7(7), 953-964 (2006-04-26)
Colonisation of the gastrointestinal tract by anaerobic bacteria, protozoa, trematodes, cestodes and/or nematodes and other infectious pathogens, including viruses, represents a major cause of morbidity and mortality in Africa, South America and southeast Asia, as well as other parts of
Karim Debache et al.
Experimental parasitology, 129(2), 95-100 (2011-08-02)
The cationic arylimidamide DB750 and the thiazolide nitazoxanide had been shown earlier to be effective against Neospora caninum tachyzoites in vitro with an IC(50) of 160nM and 4.23μM, respectively. In this study, we have investigated the effects of DB750 and
Drug repurposing approach identifies inhibitors of the prototypic viral transcription factor IE2 that block human cytomegalovirus replication
Mercorelli B, et al.
Cell Chemical Biology, 23(3), 340-351 (2016)
Benjamin Speich et al.
PLoS neglected tropical diseases, 6(6), e1685-e1685 (2012-06-09)
The currently used anthelmintic drugs, in single oral application, have low efficacy against Trichuris trichiura infection, and hence novel anthelmintic drugs are needed. Nitazoxanide has been suggested as potential drug candidate. The efficacy and safety of a single oral dose
Cirle A Warren et al.
Antimicrobial agents and chemotherapy, 56(8), 4103-4111 (2012-05-16)
Clostridium difficile infection (CDI) is a serious diarrheal disease that often develops following prior antibiotic usage. One of the major problems with current therapies (oral vancomycin and metronidazole) is the high rate of recurrence. Nitazoxanide (NTZ), an inhibitor of pyruvate:ferredoxin

商品

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门